Thank you to our partners

Genethon

Genethon, created by the AFM-Telethon, has the mission to make innovative  gene therapy treatments available to patients affected with rare genetic diseases. To meet this challenge Genethon has assembled the technical and human resources needed to accelerate the medical application of scientific discoveries arising from fundamental research. Strong translational research programs engage multi-disciplinary teams and are supported by a first rate technological platform and cGMP facility

The pipeline of Genethon includes products currently in international clinical trials and at preclinical stages, for immune deficiencies, muscular dystrophies, ocular and liver diseases. These products are developed either with Genethon as sponsor, or in partnership with private companies and academic institutions.

Oxford Biomedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines. The Company has a platform of gene delivery technologies, which are predominately based on highly engineered viral systems.

Oxford Genetics

Oxford Genetics is a synthetic biology company taking an engineering approach to DNA, virus and cell line design, optimization and development. The business has a number of technologies enabling the delivery of complex solutions for the life sciences, including proprietary plasmids for protein manufacture, and improved lentivirus production systems for gene therapy applications. These systems include proprietary promoters to maximize yield and have been developed using proprietary bioinformatics software for gene optimization. Our proprietary bioinformatics and DNA design algorithms are designed to improve recombinant protein expression. Oxford Genetics Ltd has a track record of delivering DNA design and cell line development projects for the improved production of antibodies, vaccines and viruses.

Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention. Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals.

cobra:bio

Cobra Biologics is a leading international contract development and manufacturing organisation (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. Cobra has two GMP approved facilities in Sweden and the UK, each with specific expertise tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market. As a trusted provider and a key partner in the drug development and commercialisation process, we take pride in our manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries. Cobra takes pride in manufacturing excellence, delivering what we promise and helping our customers to develop drugs for the benefit of patients.

Bio-Techne

Bio-Techne® has united some of the most referenced brands in Life Sciences: R&D Systems®, Novus Biologicals®, Tocris®, ProteinSimple® and Advanced Cell Diagnostics®. Our family of brands collaborate to provide over 50,000 products for Life Science research. We have over 350,000 journal Exhibitor citations, showing that our combined experience is trusted.

Fluidigm

Fluidigm Corp creates, manufactures, and markets technologies and life-science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon microfluidics and mass cytometry technologies.

Merck BioReliance® Services

The unique offering we have in support of cell and gene therapy includes cGMP Manufacturing services for viral gene therapy, biosafety testing services for cell and gene therapy products and gene editing technologies.

Pfizer

Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products.

AveXis

AveXis is a clinical-stage gene therapy company focused on developing novel treatments and ensuring access for patients and families affected by rare and life-threatening neurological genetic diseases. Our goal is to utilise cutting-edge science to deliver a functional copy of a lost or defective gene, using a single-dose delivery method.

Synpromics

Synpromics is the leader in gene control, improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data-driven design. The Company has developed PromPT®, its multi-dimensional bioinformatics database, that enables product-specific promoter design and selection empowering the next generation of cell and gene based medicines and bioprocessing applications. The Company operates in a diverse range of fields, including broad applications in cell and gene-based medicine, biologics manufacturing and viral vector bioprocessing. Current partners include Audentes, Biomarin, uniQure, AGTC, Solid Biosciences, Adverum Biotechnologies and Sartorius-Stedim Cellca, as well as numerous undisclosed partners in the pharmaceutical sector.